mam01
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2023 (NCT05891236)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumINHIBITOR
Plasmodium falciparum inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06408857 | Phase 1 | Jan 31, 2025 | Bill and Melinda Gates Foundation |
| NCT05891236 | Phase 1 | Aug 14, 2023 | Bill and Melinda Gates Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 2 | 1 | 2023 |
1 organizations
Page 1 / 1